AZD-1283 is an antagonist of P2Y12 receptor which was developed by AstraZeneca for the treatment of arterial thrombosis. The drug was tested in pre-clinical studies, however its develoment was terminated.

Narwedine, (±)- is an immediate precursor to the therapeutically valuable alkaloid (-)-galanthamine. Galantamine is a competitive and reversible cholinesterase inhibitor used for the treatment of mild to moderate Alzheimer's disease and various other memory impairments. Narwedine pronounced antinarcotic action, facilitates the transmission of nervous excitation in n- and mcholinergic synapses. Stimulates respiration and possessed a brief hypotensive effect.